Takakura Satoshi, Saito Motoaki, Ueda Kazu, Motegi Makoto, Takao Miho, Yamada Kyosuke, Okamoto Aikou, Niimi Shigeki, Sasaki Hiroshi, Tanaka Tadao, Ochiai Kazunori
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Int Surg. 2007 Jul-Aug;92(4):202-8.
Patients with ovarian clear cell adenocarcinoma (OCCA) show a poor response to conventional platinum-based chemotherapy. Recently, it was reported that combination chemotherapy with cisplatin plus irinotecan hydrochloride (P-CPT) achieves high response rates for primary advanced and recurrent or resistant OCCA. We retrospectively reviewed the outcome of 20 OCCA patients treated with P-CPT by the Gynecology Service at The Jikei University Hospital after initial surgery. These patients received a total of 101 cycles of P-CPT, with a median of 5 cycles each. Two complete responses (CRs) were obtained in the three patients with measurable disease, and response duration was 7 and 15 months, respectively. One patient had stable disease (SD), and the time to progression was 5 months. The estimated 3- and 5-year survival rates were 69% and 69%, respectively. Our current data and previous reports suggest that P-CPT is a candidate first-line chemotherapy regimen for OCCA.
卵巢透明细胞腺癌（OCCA）患者对传统铂类化疗反应不佳。最近有报道称，顺铂联合盐酸伊立替康（P-CPT）的联合化疗对原发性晚期、复发或耐药的OCCA有较高的缓解率。我们回顾性分析了东京慈惠会医科大学医院妇科在初次手术后采用P-CPT治疗的20例OCCA患者的治疗结果。这些患者共接受了101个周期的P-CPT治疗，平均每人5个周期。在3例可测量疾病的患者中获得了2例完全缓解（CR），缓解持续时间分别为7个月和15个月。1例患者病情稳定（SD），疾病进展时间为5个月。估计3年和5年生存率分别为69%和69%。我们目前的数据和既往报告表明，P-CPT是OCCA一线化疗方案的候选方案。
